# MEF2C

## Overview
MEF2C, or Myocyte Enhancer Factor 2C, is a gene that encodes a transcription factor pivotal in the regulation of gene expression in various tissues, including muscle and neural cells. The protein product, myocyte enhancer factor 2C, belongs to the MADS-box transcription enhancer factor 2 (MEF2) family, which plays a crucial role in cellular differentiation and development. MEF2C is particularly significant in the development of the cardiovascular system and the brain, influencing processes such as myogenesis, neurogenesis, and synaptic function. The protein interacts with numerous other proteins and DNA to regulate gene expression, and its activity is modulated through complex post-translational modifications. Mutations and dysregulation of MEF2C are linked to several neurodevelopmental disorders, cardiovascular diseases, and have implications in muscle development and function (Molkentin1996Mutational; Yuan2017MEF2C; Cosgrove2020Genes).

## Structure
MEF2C (Myocyte Enhancer Factor 2C) is a transcription factor characterized by a highly conserved structure crucial for its function in gene regulation. The protein's primary structure includes a MADS box domain at the N-terminus, comprising 56 amino acids essential for DNA binding and dimerization (Janson2001Functional). Adjacent to the MADS box is the MEF2 domain, a 29-amino acid extension that enhances DNA binding and facilitates dimerization with other homologous MEF2 proteins, as well as interactions with cofactors (Infantino2013MEF2C).

The secondary structure of MEF2C includes predicted Î±-helical configurations, particularly in the MEF2 Î² domains, which are encoded by short alternatively spliced exons (Zhu2005Alternative). These Î² domains differ structurally from the flanking regions and are absent in the Î²- isoforms, which lack the helical structure (Zhu2005Alternative).

At the tertiary level, specific regions such as amino acids 312-367 are noted for their importance in transcriptional activation, dependent on the presence of amino acids 87-311 for full effect (Janson2001Functional). The C-terminal of MEF2C, which varies among family members, serves as the transcriptional activation domain and is subject to extensive alternative splicing, producing different isoforms with distinct functions (Zhang2015Alternative).

Post-translational modifications such as phosphorylation significantly enhance the transactivation function of MEF2C, particularly through the phosphorylation of specific threonine residues within the transactivation domain by p38 MAPK (Zhu2005Alternative). These modifications are crucial for regulating the activity and stability of MEF2C, highlighting the complex regulation of this transcription factor at multiple levels.

## Function
MEF2C (Myocyte Enhancer Factor 2C) is a transcription factor that plays a pivotal role in the regulation of gene expression across various cell types, particularly influencing developmental processes in muscle and neural tissues. It is essential for the differentiation of skeletal, cardiac, and smooth muscle cells, where it activates muscle-specific genes in cooperation with other transcription factors such as myogenic basic helix-loop-helix (bHLH) proteins (Molkentin1996Mutational). MEF2C is also crucial in the development of the cardiovascular system, as evidenced by its involvement in vasculogenesis and angiogenesis, processes vital for forming vascular networks during embryonic development (Maiti2008Vascular).

In the nervous system, MEF2C is necessary for the terminal differentiation and post-mitotic survival of neurons, playing a significant role in neurodevelopment and the maintenance of neuronal functions (Janson2001Functional). It regulates key genes involved in synaptic function and neuronal distribution, which are critical for cognitive and motor functions (Cosgrove2020Genes). Additionally, MEF2C interacts with various signaling pathways and regulatory proteins, influencing cellular processes such as apoptosis, particularly in developing neurons and endothelial cells, thereby contributing to cellular survival and tissue integrity (Pon2015MEF2).

Overall, MEF2C's function as a transcription factor is integral to the proper development and function of muscle tissues, the cardiovascular system, and the brain, underscoring its importance in human health and disease.

## Clinical Significance
MEF2C mutations and alterations are implicated in a spectrum of neurodevelopmental and neuropsychiatric disorders. MEF2C haploinsufficiency syndrome, resulting from deletions or mutations such as missense and nonsense variants, is characterized by intellectual disabilities, speech deficits, autism-like symptoms, seizures, and motor abnormalities (VreÄar2017Further; Zhang2022Progress). This syndrome also presents with severe developmental delays, lack of speech, and limited walking ability, often linked to microdeletions in the 5q14.3 chromosome region affecting MEF2C expression (Cooley2021Comprehensive).

In addition to neurodevelopmental impacts, MEF2C mutations are associated with various neurological conditions. For instance, specific mutations are linked to epilepsy syndromes, including febrile seizures and infantile spasm syndrome (ISS), and nervous system tumors where MEF2C's role is evident in tumor cell proliferation and invasion (Zhang2022Progress). The gene's involvement extends to cardiovascular disorders, as seen in familial dilated cardiomyopathy (DCM) where a specific mutation leads to significant transcriptional activity reduction, impacting heart function (Yuan2017MEF2C).

These findings underscore the critical role of MEF2C in human health and disease, highlighting the diverse clinical manifestations associated with its dysregulation.

## Interactions
MEF2C interacts with a variety of proteins and nucleic acids, playing a crucial role in muscle development and other cellular processes. It forms complexes with DNA and other proteins, such as the regulatory protein Ki-1/57, which inhibits MEF2C's DNA-binding activity (Kobarg2005MEF2C). MEF2C also interacts with TBX5, a relationship crucial for early heart development, involving their DNA-binding domains to form a complex on the MYH6 promoter (Ghosh2009Physical). Additionally, MEF2C binds to various myogenic regulatory factors (MRFs) like MyoD, Myogenin, Myf5, and MRF4 through its MADS/MEF2 domain, essential for myoblast specification and differentiation (Dong2017Myocyte).

MEF2C's interaction with protein phosphatase 1 alpha (PP1Î±) represses its transactivation properties, affecting MEF2-dependent gene expression (Perry2009Direct). Furthermore, the protein interacts with nTRIP6 in myoblasts, where nTRIP6 is recruited to MEF2C-binding regions of target genes, suggesting a co-regulatory role in transcription (Kemler2016The). These interactions highlight MEF2C's role in transcriptional regulation and its importance in developmental processes across various tissues.


## References


[1. (Zhu2005Alternative) Bangmin Zhu, Bindu Ramachandran, and Tod Gulick. Alternative pre-mrna splicing governs expression of a conserved acidic transactivation domain in myocyte enhancer factor 2 factors of striated muscle and brain. Journal of Biological Chemistry, 280(31):28749â28760, August 2005. URL: http://dx.doi.org/10.1074/jbc.m502491200, doi:10.1074/jbc.m502491200. (79 citations) 10.1074/jbc.m502491200](https://doi.org/10.1074/jbc.m502491200)

[2. (Kobarg2005MEF2C) Claudia Bandeira Kobarg, JÃ¶rg Kobarg, Daniella P. Crosara-Alberto, ThaÃ­s Holtz Theizen, and Kleber Gomes Franchini. Mef2c dnaâbinding activity is inhibited through its interaction with the regulatory protein kiâ1/57. FEBS Letters, 579(12):2615â2622, April 2005. URL: http://dx.doi.org/10.1016/j.febslet.2005.03.078, doi:10.1016/j.febslet.2005.03.078. (20 citations) 10.1016/j.febslet.2005.03.078](https://doi.org/10.1016/j.febslet.2005.03.078)

[3. (Pon2015MEF2) Julia R. Pon and Marco A. Marra. Mef2 transcription factors: developmental regulators and emerging cancer genes. Oncotarget, 7(3):2297â2312, October 2015. URL: http://dx.doi.org/10.18632/oncotarget.6223, doi:10.18632/oncotarget.6223. (186 citations) 10.18632/oncotarget.6223](https://doi.org/10.18632/oncotarget.6223)

[4. (Ghosh2009Physical) Tushar K. Ghosh, Fei Fei Song, Elizabeth A. Packham, Sarah Buxton, Thelma E. Robinson, Jonathan Ronksley, Tim Self, Andrew J. Bonser, and J. David Brook. Physical interaction between tbx5 and mef2c is required for early heart development. Molecular and Cellular Biology, 29(8):2205â2218, April 2009. URL: http://dx.doi.org/10.1128/mcb.01923-08, doi:10.1128/mcb.01923-08. (155 citations) 10.1128/mcb.01923-08](https://doi.org/10.1128/mcb.01923-08)

[5. (Dong2017Myocyte) Chen Dong, Xue-Zhou Yang, Chen-Yan Zhang, Yang-Yang Liu, Ren-Bin Zhou, Qing-Di Cheng, Er-Kai Yan, and Da-Chuan Yin. Myocyte enhancer factor 2c and its directly-interacting proteins: a review. Progress in Biophysics and Molecular Biology, 126:22â30, July 2017. URL: http://dx.doi.org/10.1016/j.pbiomolbio.2017.02.002, doi:10.1016/j.pbiomolbio.2017.02.002. (55 citations) 10.1016/j.pbiomolbio.2017.02.002](https://doi.org/10.1016/j.pbiomolbio.2017.02.002)

[6. (Cosgrove2020Genes) Donna Cosgrove, Laura Whitton, Laura Fahey, Pilib Ã Broin, Gary Donohoe, and Derek W Morris. Genes influenced by mef2c contribute to neurodevelopmental disease via gene expression changes that affect multiple types of cortical excitatory neurons. Human Molecular Genetics, 30(11):961â970, September 2020. URL: http://dx.doi.org/10.1093/hmg/ddaa213, doi:10.1093/hmg/ddaa213. (19 citations) 10.1093/hmg/ddaa213](https://doi.org/10.1093/hmg/ddaa213)

[7. (Perry2009Direct) R. L. S. Perry, C. Yang, N. Soora, J. Salma, M. Marback, L. Naghibi, H. Ilyas, J. Chan, J. W. Gordon, and J. C. McDermott. Direct interaction between myocyte enhancer factor 2 (mef2) and protein phosphatase 1Î± represses mef2-dependent gene expression. Molecular and Cellular Biology, 29(12):3355â3366, June 2009. URL: http://dx.doi.org/10.1128/MCB.00227-08, doi:10.1128/mcb.00227-08. (50 citations) 10.1128/MCB.00227-08](https://doi.org/10.1128/MCB.00227-08)

[8. (Molkentin1996Mutational) Jeffery D. Molkentin, Brian L. Black, James F. Martin, and Eric N. Olson. Mutational analysis of the dna binding, dimerization, and transcriptional activation domains of mef2c. Molecular and Cellular Biology, 16(6):2627â2636, June 1996. URL: http://dx.doi.org/10.1128/mcb.16.6.2627, doi:10.1128/mcb.16.6.2627. (164 citations) 10.1128/mcb.16.6.2627](https://doi.org/10.1128/mcb.16.6.2627)

[9. (Zhang2015Alternative) Meiling Zhang, Bo Zhu, and Judith Davie. Alternative splicing of mef2c pre-mrna controls its activity in normal myogenesis and promotes tumorigenicity in rhabdomyosarcoma cells. Journal of Biological Chemistry, 290(1):310â324, January 2015. URL: http://dx.doi.org/10.1074/jbc.m114.606277, doi:10.1074/jbc.m114.606277. (45 citations) 10.1074/jbc.m114.606277](https://doi.org/10.1074/jbc.m114.606277)

[10. (Maiti2008Vascular) Debasish Maiti, Zhenhua Xu, and Elia J. Duh. Vascular endothelial growth factor induces mef2c and mef2-dependent activity in endothelial cells. Investigative Opthalmology &amp; Visual Science, 49(8):3640, August 2008. URL: http://dx.doi.org/10.1167/iovs.08-1760, doi:10.1167/iovs.08-1760. (79 citations) 10.1167/iovs.08-1760](https://doi.org/10.1167/iovs.08-1760)

[11. (Yuan2017MEF2C) Fang Yuan, Zhao-Hui Qiu, Xing-Hua Wang, Yu-Min Sun, Jun Wang, Ruo-Gu Li, Hua Liu, Min Zhang, Hong-Yu Shi, Liang Zhao, Wei-Feng Jiang, Xu Liu, Xing-Biao Qiu, Xin-Kai Qu, and Yi-Qing Yang. Mef2c loss-of-function mutation associated with familial dilated cardiomyopathy. Clinical Chemistry and Laboratory Medicine (CCLM), 56(3):502â511, September 2017. URL: http://dx.doi.org/10.1515/cclm-2017-0461, doi:10.1515/cclm-2017-0461. (20 citations) 10.1515/cclm-2017-0461](https://doi.org/10.1515/cclm-2017-0461)

[12. (VreÄar2017Further) Irena VreÄar, Josie Innes, Elizabeth Jones, Helen Kingston, William Reardon, Bronwyn Kerr, Jill Clayton-Smith, and Sofia Douzgou. Further clinical delineation of the mef2c haploinsufficiency syndrome: report on new cases and literature review of severe neurodevelopmental disorders presenting with seizures, absent speech, and involuntary movements. Journal of Pediatric Genetics, 06(03):129â141, April 2017. URL: http://dx.doi.org/10.1055/s-0037-1601335, doi:10.1055/s-0037-1601335. (46 citations) 10.1055/s-0037-1601335](https://doi.org/10.1055/s-0037-1601335)

[13. (Cooley2021Comprehensive) Jessica A. Cooley Coleman, Sara M. Sarasua, Luigi Boccuto, Hannah Warren Moore, Steven A. Skinner, and Jane M. DeLuca. Comprehensive investigation of the phenotype of <scp>mef2cârelated</scp> disorders in human patients: a systematic review. American Journal of Medical Genetics Part A, 185(12):3884â3894, June 2021. URL: http://dx.doi.org/10.1002/ajmg.a.62412, doi:10.1002/ajmg.a.62412. (12 citations) 10.1002/ajmg.a.62412](https://doi.org/10.1002/ajmg.a.62412)

[14. (Janson2001Functional) C.G Janson, Y Chen, Y Li, and D Leifer. Functional regulatory regions of human transcription factor mef2c. Molecular Brain Research, 97(1):70â82, December 2001. URL: http://dx.doi.org/10.1016/s0169-328x(01)00187-5, doi:10.1016/s0169-328x(01)00187-5. (33 citations) 10.1016/s0169-328x(01)00187-5](https://doi.org/10.1016/s0169-328x(01)00187-5)

[15. (Zhang2022Progress) Zhikun Zhang and Yongxiang Zhao. Progress on the roles of mef2c in neuropsychiatric diseases. Molecular Brain, January 2022. URL: http://dx.doi.org/10.1186/s13041-021-00892-6, doi:10.1186/s13041-021-00892-6. (21 citations) 10.1186/s13041-021-00892-6](https://doi.org/10.1186/s13041-021-00892-6)

[16. (Kemler2016The) Denise Kemler, Oliver Dahley, Sven RoÃwag, Margarethe Litfin, and Olivier Kassel. The lim domain protein ntrip6 acts as a co-repressor for the transcription factor mef2c in myoblasts. Scientific Reports, June 2016. URL: http://dx.doi.org/10.1038/srep27746, doi:10.1038/srep27746. (12 citations) 10.1038/srep27746](https://doi.org/10.1038/srep27746)

[17. (Infantino2013MEF2C) Vittoria Infantino, Paolo Convertini, Alessio Menga, and Vito Iacobazzi. Mef2c exon Î±: role in gene activation and differentiation. Gene, 531(2):355â362, December 2013. URL: http://dx.doi.org/10.1016/j.gene.2013.08.044, doi:10.1016/j.gene.2013.08.044. (28 citations) 10.1016/j.gene.2013.08.044](https://doi.org/10.1016/j.gene.2013.08.044)